Celladon Announces Successful Preclinical Trials in Congestive Heart Failure

Celladon announced that its collaborators presented successful results of heart failure trials conducted in large animal models.

Roger Hajjar and David Kaye presented data on treatment of advanced heart failure in preclinical models using Celladon's therapeutic agents targeting the Sarcoplasmic Reticulum ATPase2a (SERCA2a) pump. The SERCA2a pump is a central control point for progression of heart failure, and treatments targeting this pathway essentially reversed the deterioration in cardiac function in experimental models.

Furthermore, the therapeutic agents were delivered using delivery methodologies easily translated into clinical procedures for human heart failure, which are similar to how coronary angioplasty is performed.